Wednesday - April 9, 2025
IMFINZI (durvalumab) Approved in the US as First and Only Perioperative Immunotherapy for Patients With Muscle-Invasive Bladder Cancer
April 01, 2025
WILMINGTON, Delaware, April 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

IMFINZI (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone

AstraZeneca's IMFINZ . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products